Organisation paid for research Program year 2025 Source: CMS Open Payments

Cenexel Cit

Neither a doctor nor a teaching hospital

Research payments

$5,486,758

9 payments

Through program year 2025, Cenexel Cit is reported as receiving $5,486,758 in research payments, across 9 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$5,057,755	6
2024	Research	$429,003	3

Breakdown

Who paid Research payments · program years 2024–2025

E.R. Squibb & Sons, L.L.C. $5,486,758 9 payments

Studies the money was for Research payments · program years 2024–2025

A Phase 3b, Open-label, Multicenter, Two-Period, Slow-titration and Food Effect Study to Assess the Safety and Efficacy of KarXT in Participants with DSM-5 Schizophrenia $4,256,444 1 payment
Phase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1) $398,016 2 payments
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) $323,298 2 payments
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $293,014 2 payments
An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants with DSM-5 Schizophrenia $185,000 1 payment
An Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Subjects With DSM-5 Schizophrenia $30,987 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.